Final 2027 Medicare Reimbursement Rulings and Coverage Expansion to New Place of Service Reinforce Growth Outlook

HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) ("Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the third quarter ended September 30, 2026 and provided an operational and business update.

Third Quarter and First Nine Months 2026 Financial Summary

"We have also observed a shift of patients and wound care volumes back to hospital-based settings and enjoyed our highest quarter ever of Aurix revenues in the hospital setting,” continued Mr. Jorden. "Since this year’s first quarter, our HOPD Aurix sales as a percentage of total wound care sales has more than doubled. The economics in hospital settings are strong, and we will continue to pursue and emphasize growth opportunities in this segment. We remain confident that autologous PRP and Aurix in particular are well positioned for continued long term attractive growth.”

"As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth. The funding of the secured notes under the loan agreement in several tranches this year was done with these priorities in mind,” concluded Mr. Jorden.

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s anticipated growth opportunities and market positioning, including in the hospital outpatient setting, expectations regarding Medicare reimbursement and coverage changes, including the expansion of coverage to nursing home treatments, and their impact on demand for and pricing of Aurix, anticipated pricing actions, movement toward breakeven operations, and Nuo's ability to strengthen its capital structure. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as "believes,” "plans,” "anticipates,” "projects,” "estimates,” "expects,” "intends,” "strategy,” "future,” "opportunity,” "may,” "will,” "should,” "could,” "potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.